NAV

3-(cyclohexylamino)propanesulfonic acid

Identification

Generic Name
3-(cyclohexylamino)propanesulfonic acid
DrugBank Accession Number
DB02219
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 221.317
Monoisotopic: 221.108564169
Chemical Formula
C9H19NO3S
Synonyms
  • 3-(Cyclohexylamino)-1-propanesulfonic acid
  • 3-Cyclohexylaminopropane-1-sulphonic acid
  • CAPS
External IDs
  • WAS-12
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cyclohexylamines. These are organic compounds containing a cyclohexylamine moiety, which consist of a cyclohexane ring attached to an amine group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Cyclohexylamines
Direct Parent
Cyclohexylamines
Alternative Parents
Sulfonyls / Organosulfonic acids / Alkanesulfonic acids / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aliphatic homomonocyclic compound / Alkanesulfonic acid / Amine / Cyclohexylamine / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organic sulfonic acid or derivatives / Organopnictogen compound / Organosulfonic acid
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
4W981O1LXP
CAS number
1135-40-6
InChI Key
PJWWRFATQTVXHA-UHFFFAOYSA-N
InChI
InChI=1S/C9H19NO3S/c11-14(12,13)8-4-7-10-9-5-2-1-3-6-9/h9-10H,1-8H2,(H,11,12,13)
IUPAC Name
3-(cyclohexylamino)propane-1-sulfonic acid
SMILES
OS(=O)(=O)CCCNC1CCCCC1

References

General References
Not Available
PubChem Compound
70815
PubChem Substance
46506121
ChemSpider
63979
ZINC
ZINC000002004372
PDBe Ligand
CXS
PDB Entries
1n0x / 1rzl / 1y1j / 1y56 / 1z70 / 2a26 / 2a32 / 2bj0 / 2bk9 / 2dd7 …
show 90 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAsthma1
3CompletedTreatmentClinical Efficacy / Effects, Drug Side / Treatment Efficacy1
3CompletedTreatmentESI-related Bleeding1
2CompletedTreatmentFatty Liver / Steatohepatitis1
2, 3CompletedTreatmentMultiple Sclerosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.51 mg/mLALOGPS
logP-0.84ALOGPS
logP-0.53Chemaxon
logS-2.2ALOGPS
pKa (Strongest Acidic)-0.53Chemaxon
pKa (Strongest Basic)10.45Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area66.4 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity55.26 m3·mol-1Chemaxon
Polarizability24.01 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.7722
Blood Brain Barrier+0.8847
Caco-2 permeable-0.6466
P-glycoprotein substrateNon-substrate0.7641
P-glycoprotein inhibitor INon-inhibitor0.8597
P-glycoprotein inhibitor IINon-inhibitor0.9496
Renal organic cation transporterNon-inhibitor0.8054
CYP450 2C9 substrateNon-substrate0.8326
CYP450 2D6 substrateNon-substrate0.8015
CYP450 3A4 substrateNon-substrate0.6776
CYP450 1A2 substrateNon-inhibitor0.8639
CYP450 2C9 inhibitorNon-inhibitor0.8601
CYP450 2D6 inhibitorNon-inhibitor0.9056
CYP450 2C19 inhibitorNon-inhibitor0.9027
CYP450 3A4 inhibitorNon-inhibitor0.9835
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9396
Ames testNon AMES toxic0.7573
CarcinogenicityNon-carcinogens0.5293
BiodegradationNot ready biodegradable0.5239
Rat acute toxicity1.6309 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7173
hERG inhibition (predictor II)Non-inhibitor0.7152
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-001i-9600000000-8d93ffc67e2fe9c40a9e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-3940000000-996536d4492b4295245f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0090000000-48f9ae02c5f210e0ea6b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0019-7930000000-fbd55811c4648589aff4
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-05fu-9510000000-d78f1cfe8f0887e72caf
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-06829f5fb7e0295d0dcc
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-053r-9100000000-25dc998aed5a0dfea2d8
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-157.5037541
predicted
DarkChem Lite v0.1.0
[M-H]-147.16689
predicted
DeepCCS 1.0 (2019)
[M+H]+157.8008541
predicted
DarkChem Lite v0.1.0
[M+H]+149.71379
predicted
DeepCCS 1.0 (2019)
[M+Na]+157.4062541
predicted
DarkChem Lite v0.1.0
[M+Na]+156.98183
predicted
DeepCCS 1.0 (2019)

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52